I can only guess why anyone would compare the prospects for Bavi with the prospects for Cotara. Laughable, if not so sad.
Cotara is a radiation product targeted at the tiny GBM market. By all accounts a pretty good product, but not in Bavi's class in any way. Bavi has demonstrated efficacy in multiple tumor types while offering a very mild side affects profile.
Not an apples and oranges comparison. More like an apples and radishes comparison.
News 
Market Data 
Discover 
